A carregar...
Publicação
Baby wish comes true with the help of Ivf - long term growth, amid short term challenges
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 3.85 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This equity research report is about the company Vitrolife. We anticipate that
increasing demand for IVF due to increasing maternal age and increasing
infertility rates will drive Vitrolife’s long-term growth. A setback could be the
APAC region's competitive environment due to its competitors' acquisitions.
We see a value driver in Vitrolife’s acquisition of genetic testing service
provider Igenomix, positively affecting Vitrolife sales growth in the future.
According to this analysis, we set a price target for Vitrolife of SEK233.51 in
2023 and hence give a buy recommendation with an expected total return of
21.34%.
Descrição
Palavras-chave
Vitrolife Ivf Valuation